IN8BIO, INC.
INAB · XNASCIK 1740279fmd_1ZGBZHQ3FPHSGN81C9THBWMQB0Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 5 | 7 | 14 | 17 | 17 | 10 |
| Total operating expenses | 9 | 15 | 29 | 30 | 31 | 20 |
| Operating income | (9) | (15) | (29) | (30) | (30) | (19) |
| Interest and investment income | – | – | – | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | (31) | (19) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (31) | (19) |
| Net income | (9) | (15) | (29) | (30) | (30) | (19) |
| Net income to common shareholders | (10) | (15) | – | – | – | – |